Kazia Therapeutics, a biotech company focused on cancer therapies, announced that CEO John Friend and Head of Corporate Strategy Jeffrey Kraws will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9, 2026. The company is developing paxalisib, an oral drug targeting brain and other cancers, which has received several FDA designations. Kazia is also advancing new preclinical programs targeting cancer resistance and immune evasion. The event will include a live webcast and one-on-one meetings with management.
Kazia Therapeutics' upcoming participation in a healthcare innovation conference is presented here with Pluang's Health-sector market data as of Oct 29, 2026 17:11 WIB: Among 150 US health stocks, 86 rose and 57 fell. ClearPoint Neuro Inc (CLPT) gained 4.17% to USD 11.00 with a balanced 50% sell/buy order split and an 11-day typical hold time, while Inovio Pharmaceuticals Inc (INO) rose 3.38% to USD 0.96 despite a 65% sell order activity and a longer 43-day hold. Amgen, Inc. (AMGN) increased 3.36% to USD 466.99, showing strong buying interest at 82% and a 73-day hold period.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
